Introduction

Polycystic ovary syndrome (PCOS) is one of the most common endocrine disorders affecting women of reproductive age, with a global prevalence of 8–13%. While its metabolic and reproductive features—such as irregular periods, hyperandrogenism, and insulin resistance—are widely discussed, the impact of PCOS on the endometrium often receives less attention. Yet the endometrium, the inner lining of the uterus, is directly affected by the hormonal disruptions inherent in PCOS. Understanding this connection is essential for preventing complications like endometrial hyperplasia and cancer, preserving fertility, and ensuring long-term gynecologic health. This article provides a comprehensive, evidence-based review of how PCOS influences endometrial health and what steps can be taken to manage risks effectively.

What Is PCOS?

PCOS is diagnosed when at least two of the following three criteria (the Rotterdam criteria) are present: ovulatory dysfunction (typically manifesting as irregular or absent menstrual cycles), clinical or biochemical evidence of hyperandrogenism (elevated androgens such as testosterone), and polycystic ovarian morphology on ultrasound. The condition is frequently accompanied by metabolic disturbances, especially insulin resistance and compensatory hyperinsulinemia, which can affect the entire body, including the endometrium.

Women with PCOS often experience persistent anovulation, meaning the ovaries do not release an egg regularly. This lack of ovulation leads to a chronic state of unopposed estrogen exposure, where estrogen continues to stimulate the endometrium without the counterbalancing effect of progesterone (which normally rises after ovulation). Over time, this estrogen-dominated environment can cause abnormal endometrial growth, setting the stage for hyperplasia and potentially cancer.

The heterogeneity of PCOS means that presentations vary widely. Some women have mainly metabolic features, others have predominantly androgen-related symptoms, and still others have primarily ovulatory dysfunction. Regardless of the subtype, the common thread of anovulation and hormonal imbalance puts the endometrium at risk.

The Endometrium: Structure and Function

The endometrium is a dynamic, hormone-sensitive tissue that lines the uterine cavity. It consists of a functional layer that is shed during menstruation and a basal layer that regenerates the functional layer each cycle. During the follicular phase of the menstrual cycle, rising estrogen from developing follicles stimulates proliferation of the endometrium, thickening it in preparation for possible implantation. After ovulation, the corpus luteum produces progesterone, which transforms the endometrium into a secretory state, making it receptive to an embryo. If conception does not occur, progesterone levels drop, triggering breakdown and shedding of the functional layer.

This cyclical process depends on a precise balance between estrogen and progesterone. When ovulation fails to occur, progesterone is not produced, and the endometrium remains under continuous estrogen stimulation. This unopposed estrogen leads to persistent proliferation, aberrant glandular and stromal growth, and eventually to disordered architecture known as endometrial hyperplasia.

The endometrial response to hormonal signals is mediated by estrogen receptors (ERs) and progesterone receptors (PRs). In PCOS, the estrogenic milieu may alter receptor expression, contributing to abnormal growth patterns. Additionally, insulin resistance and hyperinsulinemia can directly influence endometrial cells, promoting proliferation through pathways such as PI3K/Akt and MAPK. These mechanisms further explain why women with PCOS are at heightened risk for endometrial pathology.

How PCOS Affects Endometrial Health

Hormonal Imbalances

The primary driver of endometrial changes in PCOS is anovulation, which leads to a relative deficiency of progesterone. Progesterone normally opposes estrogen’s proliferative effects by inducing differentiation and apoptosis in endometrial cells. Without adequate progesterone, the endometrium continues to grow unchecked. Additionally, hyperandrogenism—elevated testosterone, androstenedione, and other androgens—may have direct effects on the endometrium. While the role of androgens in endometrial health is still being studied, evidence suggests that androgen receptors are present in endometrial tissue, and excess androgens may promote proliferation or modify hormone receptor sensitivity.

Insulin resistance compounds these effects. Hyperinsulinemia stimulates ovarian androgen production and reduces sex hormone‑binding globulin (SHBG), leading to higher free estrogen and androgen levels. Insulin itself can act as a growth factor on endometrial cells, activating mitogenic signaling cascades. This triple threat—unopposed estrogen, hyperandrogenism, and hyperinsulinemia—creates a potent pro‑proliferative environment in the endometrium.

Endometrial Hyperplasia

Endometrial hyperplasia is defined as the abnormal proliferation of endometrial glands relative to stroma. It is classified into two main types: hyperplasia without atypia (benign but requiring monitoring) and atypical hyperplasia (a precancerous condition). The risk of progression to endometrial cancer is significantly higher when atypia is present, with estimates of up to 30% over several years if left untreated.

Women with PCOS have a two‑ to three‑fold increased risk of endometrial hyperplasia compared to women without PCOS. The risk is especially pronounced in those with long‑standing anovulation, severe insulin resistance, or a body mass index above 30. A study published in the Journal of Clinical Endocrinology & Metabolism found that approximately 30–40% of women with PCOS who underwent endometrial biopsy had evidence of hyperplasia, with about 10% showing atypical changes. These numbers underscore the importance of screening in high‑risk populations.

Endometrial Cancer Risk

The link between PCOS and endometrial cancer has been recognized for decades. Multiple meta‑analyses confirm that women with PCOS have a two‑ to four‑fold increased lifetime risk of developing endometrial cancer. The mechanism is cumulative: prolonged unopposed estrogen exposure drives hyperplasia, which can progress to endometrioid adenocarcinoma, the most common histologic type. The majority of endometrial cancers in women with PCOS are early‑stage and low‑grade, likely because the unopposed estrogen stimulates a gradual progression that may be detected before advanced disease develops. However, risk persists, and prevention remains a priority.

Factors that further increase endometrial cancer risk in PCOS include obesity, diabetes, hypertension, and nulliparity. Weight management and metabolic control are therefore critical components of risk reduction.

Managing Endometrial Health in PCOS

Medical Therapies

Progestin Therapy

The cornerstone of endometrial protection in women with PCOS is the administration of progestins to counteract unopposed estrogen. Progestins can be delivered in several forms:

  • Cyclic oral progestins: Medroxyprogesterone acetate or micronized progesterone taken for 10–14 days per month to induce regular withdrawal bleeding and promote endometrial shedding.
  • Combined hormonal contraceptives: Birth control pills (estrogen plus progestin) provide both cycle control and consistent progestin exposure, effectively suppressing endometrial proliferation. They also lower ovarian androgen production and improve acne and hirsutism.
  • Levonorgestrel‑releasing intrauterine device (LNG‑IUD): This device delivers progestin directly to the endometrial cavity, providing potent local protection with minimal systemic side effects. It is particularly effective for treating endometrial hyperplasia without atypia and is an excellent long‑term option for women who do not desire pregnancy.

For women with atypical hyperplasia, more intensive progestin therapy (often high‑dose oral progestins or LNG‑IUD) is recommended, along with close surveillance including repeat endometrial biopsies every three to six months. Surgical management, such as hysterectomy, may be considered for those who have completed childbearing or have persistent disease.

Metformin

Metformin, an insulin‑sensitizing agent, has been shown to improve ovulatory function and reduce hyperinsulinemia in women with PCOS. Studies indicate that metformin may also have direct antiproliferative effects on endometrial cells and can lower the risk of hyperplasia. While metformin alone is not sufficient for endometrial protection in all women, it is a valuable adjunct to progestin therapy, especially in those with insulin resistance.

Lifestyle Interventions

Weight loss of just 5–10% of total body weight can restore ovulation in many women with PCOS, thereby normalizing the hormonal environment and reducing endometrial risk. A diet low in refined carbohydrates and rich in fiber, healthy fats, and lean protein helps improve insulin sensitivity. Regular physical activity—at least 150 minutes per week of moderate‑intensity exercise—further enhances metabolic health and supports weight maintenance. Lifestyle changes also reduce circulating androgens and increase SHBG, which indirectly protects the endometrium.

While lifestyle modification is foundational, it may not be sufficient as a sole intervention for endometrial protection, especially in women with a long history of anovulation or prior hyperplasia. Combination with medical therapy is often necessary.

Surgical Options

For women who have completed childbearing, hysterectomy is definitive treatment for atypical hyperplasia or early‑stage endometrial cancer. However, for those wishing to preserve fertility, conservative management with progestins and close monitoring is preferred. Hysteroscopic resection of focal hyperplasia or polyps may be performed to evaluate and treat localized disease. In cases of severe hyperplasia that does not respond to progestins, endometrial ablation is occasionally used, but this technique sacrifices the ability to obtain future biopsies and is not recommended for women at risk of malignancy.

Monitoring and Surveillance

Women with PCOS who have irregular periods or other risk factors (obesity, age over 40, long‑standing anovulation) should undergo endometrial evaluation. Transvaginal ultrasound can measure endometrial thickness; a thickened endometrium (>10–12 mm in a non‑pregnant woman) warrants further investigation, typically with an endometrial biopsy or hysteroscopy. Screening may be repeated periodically based on risk stratification.

The American College of Obstetricians and Gynecologists (ACOG) recommends that women with PCOS who have persistent amenorrhea or abnormal bleeding undergo endometrial sampling. For those with hyperplasia without atypia, follow‑up biopsy is performed after three to six months of progestin therapy to confirm regression. If atypical hyperplasia is treated conservatively, lifelong surveillance is required.

Fertility and Endometrial Receptivity

Beyond cancer risk, PCOS affects endometrial function during fertility treatments. Even when ovulation is induced with medications like clomiphene citrate or letrozole, the endometrium may not be optimally receptive. Hyperandrogenism and insulin resistance can alter gene expression in endometrial cells, impairing decidualization and implantation. Some studies show that women with PCOS have a lower clinical pregnancy rate per embryo transfer in in vitro fertilization (IVF) cycles, potentially due to suboptimal endometrial quality.

Strategies to improve endometrial receptivity include optimizing metabolic status prior to treatment, using aromatase inhibitors (which have a better side‑effect profile on the endometrium than clomiphene), and considering frozen embryo transfer with a well‑prepared endometrium. Progesterone supplementation during the luteal phase is standard for all ovulation induction cycles.

Women with PCOS who conceive after ovulation induction should continue to be monitored for gestational diabetes and hypertensive disorders, but the focus on endometrial health extends beyond the preconception period. Postpartum, resuming progestin therapy or lifestyle measures can prevent a return to the anovulatory state and protect the endometrium in the long term.

The Role of Multidisciplinary Care

Managing endometrial health in PCOS requires collaboration among gynecologists, endocrinologists, reproductive specialists, nutritionists, and mental health professionals. The complex interplay of hormonal, metabolic, and psychosocial factors means that a one‑size‑fits‑all approach rarely works. Individualized treatment plans should address the patient’s current symptoms, reproductive goals, and long‑term health risks.

Women with PCOS often feel overwhelmed by the number of recommendations they receive. Clear communication about why endometrial monitoring matters—and how it can prevent serious complications—helps improve adherence. Shared decision‑making, with patient education about the benefits and risks of each intervention, empowers women to take an active role in their care.

Conclusion

The connection between PCOS and endometrial health is profound and clinically significant. Chronic anovulation, hyperandrogenism, and insulin resistance create a hormonal milieu that promotes endometrial proliferation, hyperplasia, and an elevated risk of cancer. Fortunately, this risk is largely modifiable through appropriate medical therapy, lifestyle modifications, and regular surveillance. By addressing the underlying hormonal imbalances with progestins, metformin, or the LNG‑IUD, and by achieving a healthy body weight, women with PCOS can dramatically reduce their endometrial risk while often improving other aspects of their health, including fertility and metabolic control.

Every woman with PCOS deserves to understand this connection and to receive proactive, evidence‑based care that goes beyond symptom management. For more information, consult resources such as the American College of Obstetricians and Gynecologists (ACOG) patient FAQ on PCOS, the Endocrine Society’s PCOS resources, or the Mayo Clinic’s comprehensive guide. For those seeking the latest research, a review article on endometrial cancer risk in PCOS published in Human Reproduction Update provides in‑depth information (doi: 10.1093/humupd/dmz044). With a comprehensive, multidisciplinary approach, the long‑term endometrial health of women with PCOS can be effectively safeguarded.